NCT04531150View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

January 16, 2021

Study Completion Date

May 16, 2021

Conditions
Pharmacokinetic
Interventions
DRUG

INV-101

Subjects will be randomized to receive INV-101 tablets

DRUG

Placebo

Subjects will be randomized to receive placebo tablets

Trial Locations (1)

Unknown

Altasciences, Montreal

Sponsors
All Listed Sponsors
lead

Inversago Pharma Inc.

INDUSTRY